Latest news with #Revelation
Memri
16-07-2025
- Politics
- Memri
Iranian TV Host Hossein Hosseini: 'Death to America' Means Death to U.S. Leaders, Not the People; American Leaders Are Barbaric and Colonialist and Deserve Curses and Death
Iranian TV host Hossein Hosseini said in a July 14, 2025 show on Ofogh TV (Iran) that this is 'Death to America Week.' He explained that the Leader of the Revelation clarified this means death to the leaders of America, not the American people. After all, he said, Americans have taken part in many protests against the government. It is the 'barbaric and colonialist nature of the American leaders' that warrants curses and death.
Business Wire
16-07-2025
- Business
- Business Wire
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences, Inc. (NASDAQ: REVB) (the 'Company' or 'Revelation'), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced dosing has been completed for the PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). As planned, a total of 5 cohorts were enrolled at 3 clinics in the United States. Several study data sets are expected during Q3 2025: these will include safety parameters, changes in hematologic parameters, in vitro evaluation of the inflammatory response in peripheral blood mononuclear cells isolated from study participants, and multiple biomarkers of activity. 'We thank our Investigators and participants for the rapid completion of dosing,' said James Rolke, Chief Executive Officer of Revelation. 'We are looking forward to sharing the study data shortly, and engaging the FDA to discuss future clinical development and approval pathways later this year.' About Gemini Gemini is an intravenously administered, proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD ®) that reduces the damage associated with inflammation by reprograming the innate immune system to respond to stress (trauma, infection, etc.) in an attenuated manner. Gemini is being developed for multiple indications including as a pretreatment to prevent or reduce the severity and duration of acute kidney injury (GEMINI-AKI program), and as pretreatment to prevent or reduce the severity and duration of post-surgical infection (GEMINI-PSI program), or infection post severe burn (GEMINI-PBI). Gemini may also be a treatment to stop or slow the progression of chronic kidney disease (GEMINI-CKD program). Revelation has conducted multiple preclinical studies demonstrating the therapeutic potential of Gemini in the target indications. Revelation previously announced positive Phase 1 clinical data for intravenous treatment with Gemini: the primary safety endpoint was met in the Phase 1 study, and results demonstrated statistically significant pharmacodynamic activity, as observed through expected changes in multiple biomarkers including upregulation of IL-10. About CKD Chronic kidney disease is a pervasive problem in the United States and world-wide. CKD is caused by chronic inflammation and can be initiated and propagated in several ways. One prevalent condition is the high blood sugar levels associated with diabetes (either Type 1 or Type 2): high blood sugar is toxic to kidney cells – it creates stress, which imitates the inflammatory process, leading to the demise of these cells with subsequent fibrosis, ultimately resulting in continuous loss of kidney function over time. High arterial blood pressure is another source of stress that initiates the inflammatory process that results in CKD. Other risk factors include heart disease, obesity, family history of CKD, or advanced age. Progression of chronic kidney damage often leads to end stage renal disease with the need for renal replacement therapy (dialysis or transplantation), resulting in significant morbidity and mortality for affected patients. Kidney disease is a leading cause of death in the United States. About AKI AKI, also known as acute renal failure, is a rapid loss of kidney function. AKI causes a build-up of waste products in the blood, making it more difficult for kidneys to maintain the correct balance of fluid in the body. AKI can also have a significant impact on other organs, such as the brain, the heart, and the lungs. About Revelation Biosciences, Inc. Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, for post-severe burn infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease. For more information on Revelation, please visit Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
Otago Daily Times
13-07-2025
- Politics
- Otago Daily Times
Future king visits waterfall
Edward, Prince of Wales (right) at the Victoria Falls on the Zambezi River with Sir Herbert Stanley, governor of Northern Rhodesia. — Otago Witness, 22.9.1925 COPIES OF PICTURE ARE AVAILABLE FROM ODT FRONT OFFICE, LOWER STUART ST, OR July 12: The Prince of Wales has reached the Victoria Falls and was greatly impressed by the famous sight. He then sailed up the Zambesi to Livingstone, the capital of Northern Rhodesia, where he was fittingly welcomed by the Northern Rhodesians. — Reuters Taking the cable car further Extensions of the present tramway line to Mornington must have been under discussion so long now that it is only really old residents who can recall a time when such a proposal was not more or less under consideration. At least two attempts in recent years to meet the demands of residents beyond the present terminus broke down after a short trial. Lately a new plan of tramway extension has taken definite shape. This is the scheme to extend the present line straight on up Mailer Street and then by a road yet to be formed continuing that line directly through to Kenmure road. Inquiries made by an Otago Daily Times reporter showed that the position is decidedly complicated. There are three departments of the City Council — Tramways, Finance, and Works — directly concerned, and this gives excellent opportunity for each to suggest that the real cause of the delay now taking place is to be found somewhere else. Cr Taverner, questioned on the subject of the delay of the Mornington extension, said that nothing further could be done till they had the new electrical drive machinery installed and working. The change over from the steam drive should be made, he thought, about the end of the month. Until then the Tramways Committee was not in a position to go on with the extension to the top of the hill. It's not either-or Evolution is said to deny Genesis. But even were the originals of Genesis still extant, the fact would still remain that God has written His Revelation in the rocks, in man's physical nature, in the rise and decay of species, as well as in man's heart and in the Scripture. Usually, the Bible is regarded as God's word to man: let it be remembered it is also man's word to God. Evolution will throw light on this record of man's outpouring to God, while at the same time it is not concerned to deny inspiration. But it does deny emphatically that a belief in evolution is incompatible with a belief in Christianity. The day is coming when the Church Universal will welcome back her intellectual sons, recognising that they, too, have not been denied the gift of inspiration by the Giver of all gifts. — editorial Trends in wallcoverings The liking for plain wallpapers appears to be on the wane. Manufacturers are now appealing to the lover of colour with an all-over design of rich-hued fruit, or a vista of massed flowers, or a summer woodland scene. One such design treats of peacocks and tulip trees against a background of ivory; another shows ripe wall-fruit in soft rich colours laid on with a stippled effect like that of a modern oil-colour. For children's delight is offered a paper bearing on a raised white ground pretty silhouetted groups, in black, of children dancing, feeding pets or watering flowers. The varnishing papers imitating tiles, once so invariable in bathrooms are nowadays felt to be unnecessarily chilly in effect, and their use is often superseded by an oil-painted paper in some fresh and pleasing colour, this specially treated paper being not only scrubbable, but absolutely impervious to steam. — ODT, 14.7.1925 (Compiled by Peter Dowden)
Business Wire
01-07-2025
- Business
- Business Wire
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025
SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences, Inc. (NASDAQ: REVB) (the 'Company' or 'Revelation'), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reverse split of its common stock following approval at its Special Meeting of Stockholders held on June 23, 2025. The reverse stock split will be effective as of the morning of July 7, 2025, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol 'REVB.' The CUSIP number for the common stock following the reverse stock split will be 76135L705. The reverse stock split is intended to increase the market price per share of the Company's common stock to regain compliance with the minimum bid continued listing requirement of The Nasdaq Capital Market. Proportionate adjustments will be made to the conversion and exercise prices of the company's warrants, restricted stock unit awards, stock options and to the number of shares issued and issuable under the Company's equity incentive plans. Separately, the Company also announced that it's ongoing PRIME Phase 1b clinical study of Gemini in CKD patients is expected to complete enrollment this month and topline data expected shortly after. For more information on Revelation, please visit Information for Stockholders Upon the effectiveness of the reverse stock split, each sixteen shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's relative interest in the Company's equity, except to the extent that the reverse stock split would have resulted in a stockholder owning a fractional share. Holders of common stock otherwise entitled to a fractional share as a result of the Reverse Stock Split because they hold a number of shares not evenly divisible by the Reverse Stock Split ratio will be rounded down to the nearest whole share. The reverse stock split will not change the par value of the common stock or modify the rights or preferences of the common stock. The Company's transfer agent, Continental Stock Transfer & Trust Co., will maintain the book-entry records for the Company's common stock. Registered stockholders holding pre-split shares of the Company's common stock electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to such broker's particular processes, and will not be required to take any action in connect with the reverse stock split. Continental Stock Transfer & Trust Co. can be reached at (212) 509-4000 or (800)-509-5586. About Revelation Biosciences, Inc. Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease. For more information on Revelation, please visit Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
Express Tribune
15-06-2025
- Entertainment
- Express Tribune
Nicholas Galitzine unveils first look as He-Man in Masters of the Universe
Nicholas Galitzine has officially wrapped filming for Masters of the Universe and is giving fans their first sneak peek at his role as He-Man. The actor took to Instagram to share a behind-the-scenes photo, showing him from behind with He-Man's iconic Power Sword, gauntlets, and battle gear. 'That's a wrap on Masters of the Universe,' Galitzine wrote in the caption. 'It's been the role of a lifetime. I put everything into it and I'm so proud of the movie we've made.' The upcoming Masters of the Universe live-action film, set for release in summer 2026, is directed by Travis Knight (Bumblebee) and written by Chris Butler, with earlier drafts by David Callaham and the Nee Brothers. Galitzine stars as Prince Adam, who transforms into the legendary hero He-Man to protect Eternia from Skeletor and other threats. The star-studded cast includes Camila Mendes as Teela, Alison Brie as Evil-Lyn, Jared Leto as Skeletor, and Idris Elba as Man-at-Arms. The film is produced by Amazon MGM Studios following Mattel's success with Barbie in 2023. To prepare for the physically demanding role, Galitzine reportedly consumed 4,000 calories daily and underwent intense training. Originally launched as a toy line in 1982, Masters of the Universe became a cultural phenomenon with its animated series and 1987 film starring Dolph Lundgren. The franchise has seen multiple reboots, including Netflix's Revelation series and She-Ra and the Princesses of Power. With Galitzine now leading a new generation of fans into Eternia, anticipation is high for what's being hailed as a major cinematic reboot of the beloved fantasy saga.
